一个前线 pembrolizumab 在卵泡淋巴瘤的第二阶段研究
Carrie Ho1,2, Songli Zhu3, Ted Gooley2
1Division of Hematology and Oncology, Department of Medicine University of Washington Seattle Washington USA.
EJHaem
|December 18, 2024
概括
前线 pembrolizumab 在毛囊淋巴瘤患者中显示出有限的疗效和显著的免疫相关不良事件. 对替代瘤微环境向策略的进一步研究是有必要的.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 瘤微环境 (TME) 和T细胞在卵泡淋巴瘤 (FL) 发病和预后方面至关重要.
- 编程死亡-1 (PD-1) 抑制功效可能在未经治疗的免疫能力较强的FL患者中最高.
研究的目的:
- 评估 pembrolizumab 作为 B 细胞淋巴瘤的初始治疗方法的疗效,特别是 FL.
- 评估前线 pembrolizumab 的反应率和与免疫相关的不良事件 (IRAE).
主要方法:
- 一项第二阶段研究招募了需要治疗的FL或边缘区域淋巴瘤的成年人.
- 患者接受了pembrolizumab (200毫克每21天一次) 长达18个周期.
- 通过CT和FDG-PET-CT评估反应;在基线和治疗期间进行了免疫分泌物概况.
主要成果:
- 招募了9名FL患者;大多数人都有晚期和高风险特征.
- 最好的整体反应率为33% (部分代谢反应),33%的患者患有稳定性疾病,33%的患者患有进展性疾病.
- 3级以上的IRAE发生在22%的患者身上 (透视膜炎,肌底炎);没有发现免疫分泌体与结果的关联.
结论:
- 前线 pembrolizumab 在FL中表现出有限的响应率.
- 布罗利祖马布与这群人群中IRAE的临床显著发病率有关.
- 针对FL中TME的替代策略需要进行调查.
更多相关视频
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.5K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.8K
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
